Findings From the Institute for Clinical and Economic Review (ICER) Now Available
Advocacy can take many forms, but what stands out most with each opportunity is the......
Wake Up Narcolepsy (WUN) is a 501(c)(3) nonprofit organization dedicated to driving Narcolepsy awareness, education and research towards improved treatments and a cure.
Narcolepsy by the Numbers
2000
Narcolepsy affects 1 in every 2,000 Americans and 3 million people worldwide.
50
It is estimated that up to 50% of patients with Narcolepsy may be undiagnosed.
20
Typical onset of Narcolepsy is between the ages of 10 and 20 years old, but can occur in early childhood.
6
On average, patients have 6 physician visits before receiving a Narcolepsy diagnosis.
Online Support GroupsFree, online support groups worldwide for people with Narcolepsy and their families. |
National SummitThis one-day summit is for people with Narcolepsy, their families, educators, clinicians and researchers. |
Clinical TrialsPatient engagement in clinical trials help find new ways to treat individuals with Narcolepsy. |
Annual Family WeekendChildren & Teens with Narcolepsy can meet others experiencing the same symptoms and challenges. |
Join Our TeamDo you share our passion for advocating on behalf of those with Narcolepsy? |
What’s New?
-
-
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
DUBLIN, June 4, 2026 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will present 21 abstracts,......
-
Future Neurology “Real-world insights into idiopathic hypersomnia symptoms, treatments, and quality of life from the ARISE study: a Plain Language Summary of Publication”
Logan D. Schneider, Amy Desmarais, Aatif M. Husain , Diane Ito, Douglas S. Fuller, Phyllis......
-
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
DUBLIN–(BUSINESS WIRE)–May 12, 2026– Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the REVITALYZ℠ double...